This session focuses on developing equal access to transplant services for the Hispanic population, as well as on how equity-based approaches can be used as a model for treatment programs for other diseases, such as sickle cell disease, immunodeficiencies, cancer, and other chronic conditions.

Join this activity to discuss how technology to treat end-stage kidney failure has advanced in recent years, including a review of clinical trials of portable devices and implantable xenotransplants, and what the future holds for the next phase of investigation into the artificial kidney and xenotransplant.

This activity will help participants to better determine the role and optimal timing of liver transplant in ACLF. It will review precipitators of ACLF associated with poorer outcomes, including bacterial infections and hepatitis B virus, and will explore posttransplant outcomes and predictors. The accuracy of current scoring systems for assessing the severity of disease and predicting survival will be discussed, including the Model for End-stage Liver Disease (MELD) score and the Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) score.

In this activity, participants will learn about the timeline for UNOS’s implementation of this flexible, points-based approach for all organ systems; how continuous distribution differs from the current system; and how this program is expected to benefit those who await organ transplant and impact future organ-allocation policy.

This activity will discuss the opportunities presented by NRP to increase the availability of donor organs and allow for extended patient survival time until transplant. The principles of NRP, effects on graft survival, potential complications, and ethical and legal concerns will be reviewed.

Despite the large increase in the number of multi-organ transplants (MOTs) performed over the past few years, challenges still exist in this arena. Among these unresolved issues are a lack of standardized MOT eligibility criteria across institutions, regions and different organ combinations. Ethical issues have also arisen regarding equity in organ allocation amidst a limited organ supply, as many MOT candidates get priority allocation for nonprimary organs versus individuals requiring that organ as a single transplant; this prioritization may impact optimal recipient and graft survival as well. In this session, learn more about multi-organ allocation and its accompanying challenges, risks, benefits, and expected outcomes, as well as the limitations of MOT for potential recipients.

This activity will review the current recommendations for screening and vaccination in both organ donors and organ recipients and will examine the current rationale and value of measuring COVID-19 antibody titers in light of possible low posttransplant sero-response and humoral response rates. Importantly, the current state of, and future implications for, transplantation in nonvaccinated patients will be discussed.

In this activity, participants will review conventional rejection-monitoring parameters and will identify current and emerging acute-rejection biomarkers. A closer look at data — regarding such biomarkers as donor-derived cell-free DNA, gene expression profiles, mRNA transcripts, immune effector pathway molecules, cell subsets and chemokines — will provide clarity about their predictive accuracy and value in rejection monitoring, as well as their ability to improve outcomes through rapid identification of transplant-organ dysfunction.

This activity will examine the safety and effectiveness of SPK and islet cell transplants in reversing hypoglycemia and achieving sustained insulin independence. Current advances in SPK and islet cell transplantation will be explored, along with complications, outcomes, patient management and post-transplant monitoring. The importance of coordination between health care professionals from multiple disciplines and specialties in facilitating transplantation success will be discussed.